Recombinant Human CD19 Protein (His Tag) Biotinylated

<strong>Recombinant Human CD19 Protein (His Tag) Biotinylated</strong>_x000D_ <strong>Catalog number:</strong> B2019248_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 31.6 kDa_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> B4 Protein, Human; CVID3 Protein, Human_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy Nat Rev Cancer. 2016 Aug 23;16(9):566-81._x000D_ 2: Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells Cancer Immunol Res. 2016 Jun;4(6):498-508._x000D_ 3: Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, Jacoby E, Besser MJ. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia Front Immunol. 2020 Jul 2;11:1347._x000D_ 4: Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, Wen F, Zhang JS, Wang F, Liu ZL, Cao YJ. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL Blood. 2022 Oct 20;140(16):1790-1802._x000D_ 5: Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities Curr Opin Oncol. 2022 Sep 1;34(5):552-558._x000D_ 6: Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 Blood. 2014 Jun 12;123(24):3750-9._x000D_ 7: Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy Cancer Discov. 2015 Dec;5(12):1282-95._x000D_ 8: Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, Vick B, Lotfi R, Wagner B, Grünewald TGP, Kobold S, Busch DH, Jeremias I, Blaeschke F, Feuchtinger T. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR Blood. 2020 Sep 17;136(12):1407-1418._x000D_ 9: Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood. 2012 Mar 22;119(12):2709-20._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/23360526">10: De Oliveira SN, Wang J, Ryan C, Morrison SL, Kohn DB, Hollis RP. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors J Transl Med. 2013 Jan 29;11:23. </a>_x000D_ _x000D_ <strong>Products Related to Recombinant Human CD19 Protein (His Tag) Biotinylated can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>